The aim of this study was to derive and validate a model to predict survival in candidates for HeartMate II (HMII) (Thoratec, Pleasanton, California) left ventricular assist device (LVAD) support.
Background
LVAD mortality risk prediction is important for candidate selection and communicating expectations to patients and clinicians. With the evolution of LVAD support, prior risk prediction models have become less valid.
Methods
Patients enrolled into the HMII bridge to transplantation and destination therapy trials (N ϭ 1,122) were randomly divided into derivation (DC) (n ϭ 583) and validation cohorts (VC) (n ϭ 539). Pre-operative candidate predictors of 90-day mortality were examined in the DC with logistic regression, from which the HMII Risk Score (HMRS) was derived. The HMRS was then applied to the VC.
Results
There were 149 (13%) deaths within 90 days. In the DC, mortality (n ϭ 80) was higher in older patients (odds ratio [OR]: 1.3, 95% confidence interval [CI]: 1.1 to 1.7 per 10 years), those with greater hypoalbuminemia (OR: 0.49, 95% CI: 0.31 to 0.76 per mg/dl of albumin), renal dysfunction (OR: 2.1, 95% CI: 1.4 to 3.2 per mg/dl creatinine), coagulopathy (OR: 3.1, 95% CI: 1.7 to 5.8 per international normalized ratio unit), and in those receiving LVAD support at less experienced centers (OR: 2.2, 95% CI: 1.2 to 4.4 for Ͻ15 trial patients). Mortality in the DC low, medium, and high HMRS groups was 4%, 16%, and 29%, respectively (p Ͻ 0.001). In the VC, corresponding mortality was 8%, 11%, and 25%, respectively (p Ͻ 0.001). HMRS discrimination was good (area under the receiver-operating characteristic curve: 0.71, 95% CI: 0.66 to 0.75).
Conclusions
The HMRS might be useful for mortality risk stratification in HMII candidates and may serve as an additional tool in the patient selection process. Left ventricular assist device (LVAD) support is increasingly being used for patients with refractory heart failure as either a bridge to transplantation (BTT) or destination therapy (DT). Through June 2012, over 4,000 LVAD implants have been reported to the U.S. INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) (1) , and it is estimated that 30,000 to 100,000 individuals annually in the United States could potentially benefit from LVAD support. With so many patients potentially in need of a device that carries (simultaneously) associated medical and societal benefits and burdens, careful patient selection is paramount.
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In a young and evolving field such as mechanical circulatory support (MCS), risk modeling for the purposes of LVAD patient selection and patient and family education is in a constant state of revision. Increasing clinical experience, refinements in device technology, and information gleaned from studies on patient selection (2) (3) (4) , as well as pre-and post-operative management strategies have led to improvements in patient survival from 52% at 1 year on pulsatile LVAD support (5) to Ͼ85% for BTT patients (6), and 73% for DT patients (7) supported with continuous flow LVAD technology. At present, the destination therapy risk score (DTRS) and INTERMACS profiles are the most widely used LVAD risk prediction tools (2) . Derived in the pulsatile LVAD era, the DTRS was recently shown to provide poor discrimination for BTT patients and only modest discrimination for DT patients supported with continuous flow LVADs (8) . However, the utility of both tools for assessing LVAD candidate risk in the contemporary LVAD era is in question, and a reassessment and revision of LVAD candidate risk prediction is warranted.
The primary objective of this analysis was to develop and validate a risk model for predicting LVAD candidate outcome in the "continuous flow era" of MCS. The second objective was to identify predictors of longer-term survival, independent of LVAD operative success.
Methods

Patient cohort. Patients enrolled between March 2005 and
January 2010 into either the HeartMate II (HMII) (Thoratec, Pleasanton, California) BTT or DT clinical trials who received a HMII LVAD (N ϭ 1,122) were selected for this study. Both HMII trials were prospective multicenter studies designed to assess the morbidity and mortality of subjects with end-stage heart failure undergoing implantable LVADs for long-term MCS. Details of the design, methods, and results of both the BTT (9,10) and DT trials (11) have been previously reported. Patients receiving the HMII for compassionate use or as an exchange for a previous HeartMate XVE were excluded. All patients provided written informed consent before study participation, and local institutional review board approval was provided by all enrolling centers. Statistical analysis. DESCRIPTIVE STATISTICS. Data analysis was performed with SAS (version 9.2, Cary, North Carolina). Continuous data were evaluated for normality, and accordingly, between-group comparisons with Student t or Mann-Whitney testing were performed. Categorical data were compared with Fisher exact test.
DERIVATION AND VALIDATION OF THE HMII RISK
SCORE. HMII patients enrolled into both trials were consolidated and then randomly divided into derivation (n ϭ 583) and validation (n ϭ 539) cohorts. The derivation cohort was used to develop a model for calculation of a patient-specific risk estimate, termed the HeartMate II Risk Score (HMRS), for predicting LVAD candidate 90-day mortality. Unadjusted predictors of mortality were identified from logistic regression comparisons of baseline clinical (patient demographic data, body mass index, heart failure etiology, pre-operative vasopressor and inotrope use), pre-operative laboratory (white blood count, hematocrit, platelet count, serum sodium, blood urea nitrogen, creatinine, total bilirubin, albumin, protein, alanine and aspartate aminotransferase, international normalization ratio [regardless of warfarin use]), and cardiopulmonary hemodynamic data (right atrial [RA] pressure, pulmonary artery pressures, cardiac index, pulmonary vascular resistance). Hemodynamic and laboratory measures were obtained Յ48 h before LVAD implant.
Clinically relevant risk correlates from prior LVAD risk modeling studies (age, sex, DT indication, pre-operative ventilator and/or intra-aortic balloon pump (IABP) support, pre-operative vasodilator, vasopressor and/or inotrope support, platelet count, total bilirubin, aspartate aminotransferase, blood urea nitrogen, serum creatinine, hematocrit, international normalized ratio [INR] , albumin, mean pulmonary artery pressure, RA pressure, and right ventricular stroke work index, and implanting center LVAD study volume) (1) (2) (3) 12, 13) were then manually entered into stepwise multivariable logistic analysis (exit criteria p Ն 0.05). Correlated variables (e.g., RA pressure and right ventricular stroke work index) were not entered simultaneously, and only 8 to 10 variables were entered at one time to avoid model "overfitting." Center volume was defined as the volume of LVADs implanted by the center of study during the entire HeartMate BTT or DT study period. To determine center volume thresholds, patients were first dichotomized at the 10th, 15th, 20th, and 25th percentiles on the basis of the total volume of HMIIs implanted at the study center. The dichotomization threshold was selected as the smallest percentile value for center volume at which statistically significant differences in survival were observed. This was also the center volume demonstrated to be of importance by Lietz et al. (13) . Model discrimination and calibration was evaluated with the area under the receiver-operating characteristic curve (AUC) and Hosmer-Lemeshow goodness of fit tests, respectively.
The continuous HMRS was first dichotomized into deciles of risk in order to derive the low, medium, and high HRMS categories. The deciles were then examined and consolidated into 3 (censoring for transplant or device explant for ventricular recovery). Survival differences between the 3 groups were compared with the Pearson chi-square test. When significant differences between groups were observed, post hoc comparisons were performed with the Fisher exact test. To avoid bias in model development, the validation cohort was only analyzed after the risk model was derived.
COMPARISON OF HMRS WITH DTRS AND MODEL FOR END-STAGE LIVER DISEASE.
The HMRS was compared with pre-operative DTRS (8) and the United Network for Organ Sharing-modified model for end-stage liver disease (MELD) scores that has recently been shown to be predictive of survival in LVAD patients (3). Receiver-operating characteristic curves for predicting 90-day survival on the basis of HMRS, DTRS, and MELD were generated for the total study cohort. The AUCs were calculated and compared between HMRS and DTRS as well as HMRS and MELD with the methodology described by DeLong et al. in SAS (14) .
Predictors of long-term survival. Long-term survival on the basis of HMRS category was estimated with KaplanMeier methods, and survival was compared with log-rank testing. Cox proportional hazards modeling was then used to identify correlates of long-term survival in patients who survived the initial 90-day post-operative period.
Results
Characteristics of the derivation and validation cohorts.
The derivation and validation cohorts were similar with regard to baseline demographic data, pre-operative hemodynamic status, laboratory values, and medication use (Table 1) . Median LVAD support durations were 347 and 332 days in the derivation cohort and validation cohort, respectively (p ϭ 0.84), and Kaplan-Meier survivals were similar (p ϭ 0.84) (Fig. 1) .
Correlates of mortality after LVAD implant. There were 80 deaths (14%) in the derivation cohort (n ϭ 583) during the 90-day post-operative period. Expired patients tended to be older, had greater degrees of hypoalbuminemia, coagulopathy (higher INR), and poorer renal function (higher creatinine) (see Table 2 ; complete listing available in the Online Table) . Pre-operative warfarin was used in only 39 patients and was not correlated with survival, suggesting that a higher INR was a risk factor for mortality irrespective (Table 3) . Preoperative IABP and ventilator support and vasoactive medication requirements were not associated with worse outcome. LVAD indication (BTT vs. DT) was also not predictive of outcome in the multivariable model (see footnote of Table 3 for covariates entered into the model). The HMRS and post-operative outcomes in derivation cohort. With logistic regression estimates for 90-day survival, a patient pre-operative HMRS was derived as shown in The HMRS score cutoffs for the 3 risk groups were: low risk (HRMS Ͻ1.58), medium risk (1.58 ՅHMRS Յ2.48), and high risk (HMRS Ͼ2.48). Ninety-day mortality in these 3 groups was 4%, 16%, and 29%, respectively (p Ͻ 0.001) (Fig. 2) . Pair-wise comparisons showed that both the high-and medium-risk groups had significantly worse outcome than the low-risk group (p Ͻ 0.001). Validation of the HMRS. The median (25th to 75th percentile) HMRS in the validation cohort was 1.71 (1.10 to 2.31) and was similar to that of the derivation cohort (p ϭ 0.27). Like the derivation cohort, survivors in the validation cohort had significantly lower HMRS than deaths (HMRS: 1.66 [25th, 75th percentile: 1.05 to 2.25] vs. HMRS: 2.11 [1.47 to 2.74], p Ͻ 0.001). The 90-day mortality for the low-, medium-, and high-risk HMRS groups was 8%, 11%, and 25%, respectively (p Ͻ 0.001) (Fig. 2) . Patients in the validation cohort high-risk HRMS group also had significantly worse outcome than both low-(p Ͻ 0.001) and medium-risk (p ϭ 0.002) groups. However, comparison of outcome for patients within the low-versus medium-risk group did not reach statistical significance (p ϭ 0.25). The Hosmer-Lemeshow chi-square in the validation cohort was 1.04 (p ϭ 0.31). HMRS versus DTRS and MELD and by device indication. Receiver-operating characteristic curves representing the ability of the HMRS, DTRS, and MELD scores to predict 90-day mortality in the total HMII sample (derivation ϩ validation) are shown in Figure 3 . Table 4 lists the model AUCs in various patient samples (the total cohort, the derivation/validation cohorts, and the BTT/DT cohorts). The HMRS provided significantly higher risk discrimination than the DTRS when evaluated in the total HMII sample (p Ͻ 0.001). When evaluated by device intent (BTT vs. DT), the HMRS was also more discriminative than the DTRS (p Ͻ 0.05). The HMRS had a numerically higher AUC than the MELD, but statistically significant differences were only noted in the derivation cohort and the entire HMII sample. Long-term survival after LVAD implant. Figure 4 shows the Kaplan-Meier survival curves for the total HMII sample stratified by HMRS categories. Survivals at 1 year in the low-, medium-, and high-risk groups were 83 Ϯ 2%, 72 Ϯ 2%, and 58 Ϯ 3%, respectively (p Ͻ 0.001) ( Table 5 ). Pair-wise comparisons revealed that there were significant differences between the low-versus medium-(p Ͻ 0.001), low-versus high-(p Ͻ 0.001), and medium-versus high-risk (p Ͻ 0.001) groups, suggesting that the HMRS also provides discrimination of risk several months after LVAD implant. As shown in Figure 5 , HMRS risk discrimination is maintained regardless of initial device indication (i.e., BTT or DT). Conditional survival. When conditioned on surviving 90 days postoperative, the only statistically significant preoperative predictors of long-term mortality in the derivation Likewise, when the entire HMII sample was analyzed, conditional survival was similar in BTT and DT patients (Fig. 6 ).
Discussion
In this study, we developed and prospectively validated the first model for assessing patient risk in the era of continuous Values are mean Ϯ SD, n (%), or median (25th-75th percentile). *For comparison of alive versus dead at 90 days. CI ϭ confidence interval; INR ϭ international normalized ratio; IABP ϭ intra-aortic balloon pump; LVAD ϭ left ventricular assist device; OR ϭ odds ratio; PA ϭ pulmonary artery; RVSWi ϭ right ventricular stroke work index. 
and derivation from a patient cohort supported with a now-antiquated pump that was associated with a significantly higher morbidity and mortality than that of continuous flow technology. Furthermore, the DTRS excluded BTT candidates in model development and did not include validation with multicenter data. (18), findings of poor outcomes in these patients along with an improvement in MCS technology have led to a shift to slightly earlier implantation strategies, such that INTERMACS Level 1 now only comprises 14% of patient profiles at implant (1) . Levels 4 to 7 are highly subjective in assignment, are not assigned with concrete patient-level data, and have never been shown to demonstrate graded mortality risk. The INTERMACS profiles were not included in the HMII clinical trials herein and could not be included in this analysis. However, the objective nature of the HMRS might offer risk stratification within and across INTERMACS profiles. In this analysis, we included important correlates of INTERMACS Level 1 status, including pre-operative vasopressor, inotrope, IABP, and ventilator use. That these data did not contribute additional information to the HMRS suggests that preserved end-organ function, however preoperatively achieved, might be the most important predictor of successful LVAD outcome. The HMRS will also take into account the added independent risk of mortality in the elderly that is not captured in INTERMACS.
Finally, MELD scores have also been shown to be predictive of mortality in LVAD candidates, and this model performed quite well in this analysis for predicting mortality in HMII patients (3, 19) . Although the HMRS and MELD comprise similar variables, the coefficients used for MELD score calculation were derived from patients with multifactorial liver disease and no documented cardiac dysfunction. By contrast, HMRS is derived solely from patients with advanced heart failure and takes into account the impact of age and center experience on surgical outcome. By receiveroperating characteristic curve analysis, the HMRS provided a better discrimination of outcomes compared with MELD or DTRS. Uses for the HMRS. In a field with a potential for high patient morbidity and mortality, high resource use in "nonthrivers," and a large pool of medically diverse candidates, careful patient selection is critical. The HMRS is not meant to supplant or supersede clinical judgment, nor does it provide recommendation whether or not to proceed with LVAD implant. However, the HMRS can provide additional knowledge of patient risk to help in education and communication with referring cardiologists, patients, fami- Figure 4 Kaplan-Meier Survival Stratified by HMRS Group
Survival for the entire HeartMate II patient sample is shown on the basis of HeartMate II Risk Score (HMRS) group. The vertical lines on the curves correspond to the 90-day time-point at which the risk model was derived. BTT ϭ bridge to transplant; DT ϭ destination therapy. Table 4 BTT ϭ bridge to transplant; CI ϭ confidence interval; DT ϭ destination therapy; DTRS ϭ destination therapy risk score; HMRS ϭ HeartMate II risk score; MELD ϭ model for end-stage liver disease.
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The HeartMate II Risk Score and LVAD Survival lies, and the clinical LVAD team. The HMRS might highlight important goals for pre-operative optimization and identify a period of optimal patient "fitness" for surgery. All HMRS variables except for age are potentially modifiable. Targeted reduction in patient operative risk through use of pre-operative percutaneous mechanical support technologies; inotropes; and/or diuresis to amend renal (serum creatinine), hepatic/right ventricular dysfunction (INR), and inflammatory/nutritional states (albumin) might afford better outcomes. Users of the HRMS should take into account that INR values used in this study were largely measured in absence of warfarin use. LVAD risk modeling is also an important tool for the principle of "patient-centered" care. Patient-centered care requires the process of shared decision making between the patient and the clinician (20) . Studies have shown that patients want clinicians to openly discuss risks before surgery (20) . Furthermore, patients tend to poorly predict their own survival. In a study of 122 individuals with chronic heart failure, 68% of patients over estimated their survival, and the magnitude of this overestimation was large (by 40%) (21) . Presenting survival estimations with patientlevel data provides LVAD candidates information beyond that of "average" published LVAD statistics. In elderly patients and those without a realistic option for transplant, such information might play even more critically into the shared decision-making process. Study limitations. There are several limitations of this study that must be acknowledged. Even though a large cohort was studied for purposes of HMRS derivation with use of internal model validation, the clinical trial patient population herein is not representative of many non-trial patients. Thus, further validation of the HMRS in broader patient populations should be performed. The applicability of the HMRS to patients undergoing implant of other types of continuous flow devices is also not known. Finally, a secondary aim of this analysis was to also develop a model for predicting long-term survival. Although the HMRS successfully risk stratified patient survivals beyond 12 months of LVAD support, only operative survival, age, and center experience were found to be predictive of long-term success on LVAD therapy. The study did not evaluate post-operative management and the advancement or development of comorbidities during on LVAD outcomes, which should be included in future analyses.
Conclusions
Risk factors for mortality after HMII continuous flow LVAD implant in the contemporary LVAD era were identified with a large patient cohort, and a new risk model (the HMRS) was prospectively developed and validated. The HMRS might be useful for patient, family, and referring provider education, providing patient-level LVAD mortality risk assessment regardless of BTT or DT indication. The HMRS also identifies important pre-operative risk factors that might serve as targets for goal-directed interventions meant to improve LVAD candidate survival.
